EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R‐ CHOP : A Lymphoma Registry Study

Yao Yao iD, Serif Sungur, Cameron Wellard iD, Eliza Chung iD, Susan Morgan, Denise Lee iD, Geoffrey Chong, Chan Y Cheah iD, Eliza A Hawkes iD, Erica M Wood iD, Nada Hamad, Anna M Johnston iD und 1 weitere

European Journal of Haematology · 2026-12 · 117 (6) · 1573-1582

DOI: 10.1111/ejh.70295 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Haematology, online erschienen am 18.08.2026. Verfasst von Yao Yao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Gosford Hospital, Gosford, Australia. Hauptthemen laut MEDLINE: Body Mass Index, Thinness, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

BMI may capture clinically relevant differences in host reserve and treatment vulnerability in diffuse large B‐cell lymphoma (DLBCL). We evaluated the association between BMI and survival outcomes.

Methods

Adults with DLBCL receiving first‐line R‐CHOP chemoimmunotherapy from 2016 to 2026 were identified from the Lymphoma and Related Diseases Registry. BMI was analysed as underweight, normal weight/overweight, obese Class I and obese Class II/III. Overall survival (OS) and progression‐free survival (PFS) were analysed using Kaplan–Meier and Cox models adjusted for International Prognostic Index (IPI) components, sex and cardiac history.

Results

Among 1600 patients, 43 (2.7%) were underweight, 303 (18.9%) had obese Class I BMI and 198 (12.4%) had obese Class II/III BMI. At median follow‐up of 35.4 months, 342 deaths occurred, including 15 in underweight patients. OS differed by BMI category (log‐rank p = 0.017), whereas PFS did not (log‐rank p = 0.082). In complete‐case multivariable analysis, underweight BMI remained associated with inferior OS (adjusted HR, 1.89; 95% CI, 1.06–3.37). Exploratory analyses did not identify chemotherapy exposure, including upfront dose reduction, or measured malnutrition/systemic illness markers that explained this association.

Conclusions

Underweight BMI identified patients at increased risk of inferior survival, even after adjustment for IPI‐based prognostic factors. Obese BMI categories were not associated with inferior survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Body Mass IndexThinnessLymphoma, Large B-Cell, DiffuseRegistriesKaplan-Meier EstimateProportional Hazards ModelsPrognosisSurvival RateRisk FactorsProspective StudiesAustraliaNew ZealandAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeHumansMaleFemaleMiddle AgedAgedAged, 80 and overPrednisoneRituximabDoxorubicin

Stichwörter der Autor:innen

R‐CHOPbody mass indexdiffuse large B‐cell lymphomainternational prognostic indexobesityoverall survivalprogression‐free survivalunderweight

Substanzen

R-CHOP protocolPrednisoneRituximabDoxorubicinVincristineCyclophosphamide

Autor:innen und Institutionen

  • Department of Haematology, Gosford Hospital, Gosford, Australia.
  • Haematology Trials Unit, Calvary Mater Newcastle, Newcastle, Australia.
  • School of Medicine, University of Tasmania, Launceston, Australia.
  • Department of Haematology, Royal Hobart Hospital, Hobart, Australia.
  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Alfred Health, Melbourne, Australia.

ORCID-Profile: Yao Yao, Cameron Wellard, Eliza Chung, Denise Lee, Chan Y Cheah, Eliza A Hawkes, Erica M Wood, Anna M Johnston

Zitieren

APA

Yao, Y., Sungur, S., Wellard, C., Chung, E., Morgan, S., Lee, D., Chong, G., Cheah, C. Y., Hawkes, E. A., Wood, E. M., Hamad, N., Johnston, A. M., & Armytage, T. (2026). Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R‐ CHOP : A Lymphoma Registry Study. European Journal of Haematology, 117(6), 1573-1582. https://doi.org/10.1111/ejh.70295

Vancouver

Yao Y, Sungur S, Wellard C, Chung E, Morgan S, Lee D, et al. Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R‐ CHOP : A Lymphoma Registry Study. European Journal of Haematology. 2026;117(6):1573-1582. doi:10.1111/ejh.70295

BibTeX
@article{Yao2026,
  author = {Yao, Yao and Sungur, Serif and Wellard, Cameron and Chung, Eliza and Morgan, Susan and Lee, Denise and Chong, Geoffrey and Cheah, Chan Y and Hawkes, Eliza A and Wood, Erica M and Hamad, Nada and Johnston, Anna M and Armytage, Tasman},
  title = {Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R‐ CHOP : A Lymphoma Registry Study},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {117},
  number = {6},
  pages = {1573--1582},
  doi = {10.1111/ejh.70295}
}
Kostenlos starten →